Correspondence to letter to the editor on “Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0” Di Wu, Xiaojing Wang, Weiming Yan, Man-Fung Yuen, Qin Ning Clinical and Molecular Hepatology.2026; 32(3): e408. CrossRef
Chronic hepatitis B (CHB) infection remains a significant global public health concern. Functional cure, defined as hepatitis B surface antigen seroclearance with unquantifiable HBV DNA at 24 weeks off treatment, is a desirable endpoint in the treatment of CHB, yet challenging to achieve. Given the limitations of current therapies including nucleos(t)ide analogues and pegylated interferon alpha, novel agents targeting functional cure are emerging. As hepatitis B virus (HBV) is a non-cytolytic virus, liver damage stems from the host immune response towards HBV-infected cells. The innate immune response during the initial phase of HBV infection is crucial in establishing an adequate level of immunity against the virus. However, HBV adopts various mechanisms to evade the host’s innate immunity, partly contributing to the chronicity of infection. This article provides a comprehensive review on how the HBV life cycle interacts with the host’s innate immune system. The latest evidence of novel agents targeting the innate immunity will also be covered. Retinoic acid inducible gene I agonists, toll-like receptor agonists, and interferons are therapies that target the HBV evasion strategies against host’s innate immunity. While small interfering RNAs and antisense oligonucleotides are originally designed for antigen knockdown and reinvigoration of the adaptive immune response, they have also shown additional impacts on the innate immunity. With ongoing research and innovation in combination strategies, advancement in the management of CHB is anticipated in the future.
Citations
Citations to this article as recorded by
Current Status and Prospects of Clinical Research on Low-Level Viremia in Chronic Hepatitis B after Treatment 颜 刘 Advances in Clinical Medicine.2026; 16(03): 1942. CrossRef
New insights into antibody-mediated NK cell immunity in hepatitis B: Editorial on “Dissecting antibody-mediated NK cell effects reveals a cytotoxic CX3CR1⁺KLRC2⁻CD16hi subset linked to HBV outcomes” Zuzana Macek Jilkova, Caroline Aspord Clinical and Molecular Hepatology.2026; 32(3): 1448. CrossRef
Correspondence to editorial on “Dissecting antibody-mediated natural killer cell effects reveals a cytotoxic CX3CR1+KLRC2CD16hi subset linked to hepatitis B virus outcomes” Libo Tang, Yuhao Wang, Zihan Jin, Shihong Zhong, Yongyin Li Clinical and Molecular Hepatology.2026; 32(3): e384. CrossRef
Stimulation of the Stimulator of Interferon Genes Pathway Leads to Inhibition of Hepatitis B Virus Replication: Insights Into the Role of Hepatic Macrophages Mingyuan Zhang, Xiaomei Wang, Hongqin Xu, Hao Meng, Jie Zhou, Xiaoyu Wen, Yingyu Zhang, Jinglan Jin, Qinlong Jin, Guan Huei Lee, Yanhang Gao, Junqi Niu The Journal of Infectious Diseases.2026;[Epub] CrossRef
Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses Hongmin Wang, Chao Zhang, Xiaoying Li, Yaping Li, Xin Zhang, Ruonan Xu, Kaili Wang, Sa Lv, Xing Fan, Qing Wang, Shanquan Liu, Shengxian Yang, Xiaoning Zhang, Shuangsuo Dang, Fu-Sheng Wang, Junliang Fu Emerging Microbes & Infections.2026;[Epub] CrossRef
Research Progress on Mechanisms of Immune Tolerance Induced by Hepatitis B Surface Antigen in Chronic HBV Infection Li Wang Journal of Immunology Research.2026;[Epub] CrossRef
Through the implementation of hepatitis B vaccination and effective antiviral treatment over the past four decades, the hepatitis B surface antigen (HBsAg) seroprevalence of the vaccinated generation dramatically decline. The incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) also decreases. However, the elimination of HBV is still a challenge to achieve. Novel HBV biomarkers, including quantitative HBsAg, hepatitis B virus core-related antigen and HBV RNA are promising in predicting clinical phases, risks of disease progression and HBV functional cure. Current antiviral therapies, nucleoside/nucleotide and pegylated alpha-interferon, effectively decrease HCC incidence in chronic hepatitis B (CHB) patients and minimize the recurrence of HCC in patients receiving curative therapy. Novel agents under development to achieve HBV cure include direct-acting antivirals that target various stages of the HBV lifecycle and host targeting agents that enhance HBV-specific immunity. The action plans for eliminating hepatitis B in the future are universal HBV screening, early and simplified treatment as well as precision lifelong management for CHB patients. This narrative review will summarize and discuss global strategies and initiatives aimed at eliminating HBV infection.
Citations
Citations to this article as recorded by
Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches Prashant Tiwari, Istuti Saraswat, Jyoti Gupta Current Microbiology.2026;[Epub] CrossRef
Refining surveillance of hepatocellular carcinoma in chronic hepatitis B through biomarker-based risk stratification Tai-Chung Tseng, Shang-Chin Huang, Jia-Horng Kao Hepatology Communications.2026;[Epub] CrossRef
Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications Jiayan Yan, Jiayi Wang, Jian Fan, Xinyi Cui, Yuxi Zhang, Xinrong Yang, Qiang Gao, Zhenbin Ding, Zhaoyou Tang, Jia Fan, Dan G. Duda, Ao Huang, Jian Zhou Portal Hypertension & Cirrhosis.2026; 5(1): 65. CrossRef
Exploration and optimization of indole derivatives as novel anti-HBV agent with potential TLR7-agonistic effect Lihua Yang, Zibin Qiu, Xincheng Li, Jiachen Wei, Yike Ma, Weiqun Yuan, Qiuting Xu, Xiaoke Gu, Jingying Qiu Bioorganic & Medicinal Chemistry.2026; 138: 118662. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks Kui Wang, Ruchen Zhou Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
Zinc finger protein ZBTB7A suppresses hepatitis B virus replication by attenuating FXRα-mediated HBV transcription and lowering covalently closed circular DNA levels Dan Xu, Zhenyu Zhao, Beinu Guo, Zhen Wei, Chen Li, Sichen Luo, Wen Shu, Zhongliang Shen, Mengji Lu, Jiming Zhang, Hecun Zou, Fahong Li, Yong Lin Antiviral Research.2026; 252: 106469. CrossRef
Hepatitis B Research in Peru, 1988–2023: Geographic Inequities, Thematic Gaps, and Misalignment with Disease Burden Jhon Omar Palomino-Tenorio, Obert Marín-Sánchez, Jimmy Ango-Bedriñana, Ruy D. Chacón, Homero Ango-Aguilar Pathogens.2026; 15(7): 708. CrossRef
Supramolecular Self-Assembly of Lycorine with Glycyrrhizic Acid into a Nanodrug for Safe and Sustained Anti-HBV Therapy Hang Sun, Zi-Dong He, Bei-Bei Jia, Bo Yuan, Ling-Chuan Kong, Rui-Xian Xu, Qiong Wang, Wen-Jing Pan, Hao Chen, Shao-Xing Dai, Min Xu ACS Applied Bio Materials.2026; 9(15): 7143. CrossRef
Comparable Predictive Performance of Non‐VCTE–Based Machine Learning Model for HBV‐Infected Hepatocellular Carcinoma Risk Hahn Yi, Hye Won Lee, Jae Il Shin, Hyung Woong Lee, Tae Seop Lim, Beom Kyung Kim, Namkug Kim Journal of Gastroenterology and Hepatology.2026; 41(10): 3199. CrossRef
Decoding sequence recognition code of nucleic acid‐binding proteins of human‐infecting DNA viruses Meifang Tang, Shifei Yang, Haiqian Ma, Ruoying Guo, Jie Chen, Hui Zhang, Jinghan Zhang, Wei Sun, Yun Wei, Ligang Fan, Jian Yan iMeta.2026;[Epub] CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
First
Prev
